Leaders in GI Health Innovation
Ironwood Pharmaceuticals is a pioneering GI-focused biopharmaceutical company dedicated to advancing treatments for gastrointestinal diseases. Best known as originator of linaclotide (marketed as LINZESS), the US market leader for IBS-C and chronic idiopathic constipation. In 2023 the FDA approved LINZESS for pediatric functional constipation. Ironwood partners with AbbVie on US commercialization.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2019
Feb 2014
Feb 2012
Feb 2010
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
